Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02684461
Title Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UNC Lineberger Comprehsive Cancer Center Chapel Hill North Carolina 27599 United States Details
Rex Cancer Center Raleigh North Carolina 27607 United States Details
Rex Cancer Center of Wakefield Raleigh North Carolina 27614 United States Details
UT Southwestern Medical Center Dallas Texas 75390 United States Details
Inova Schar Cancer Institute Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field